Revance Therapeutics, Inc. (NASDAQ:RVNC) went up by 8.34% from its latest closing price compared to the recent 1-year high of $29.85. The company’s stock price has collected 8.26% of gains in the last five trading sessions. Press Release reported on 09/08/20 that Revance to Participate in the Morgan Stanley 18th Annual Global Healthcare Conference
Is It Worth Investing in Revance Therapeutics, Inc. (NASDAQ :RVNC) Right Now?
Revance Therapeutics, Inc. (NASDAQ:RVNC) scored a price-to-earnings ratio above its average ratio, recording x from its present earnings ratio. Plus, the 36-month beta value for RVNC is at 1.72. Opinions of the stock are interesting as 10 analysts out of 11 who provided ratings for Revance Therapeutics, Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $37.09, which is $3.39 above the current price. RVNC currently public float of 54.33M and currently shorts hold a 10.01% ratio of that float. Today, the average trading volume of RVNC was 516.37K shares.
RVNC’s Market Performance
RVNC stocks went up by 8.26% for the week, with a monthly jump of 20.82% and a quarterly performance of 34.68%, while its annual performance rate touched 126.37%. The volatility ratio for the week stands at 4.56% while the volatility levels for the past 30 days are set at 5.05% for Revance Therapeutics, Inc.. The simple moving average for the period of the last 20 days is 15.91% for RVNC stocks with a simple moving average of 49.85% for the last 200 days.
Analysts’ Opinion of RVNC
Many brokerage firms have already submitted their reports for RVNC stocks, with Mizuho repeating the rating for RVNC by listing it as a “Buy.” The predicted price for RVNC in the upcoming period, according to Mizuho is $32 based on the research report published on August 11th of the current year 2020.
Goldman, on the other hand, stated in their research note that they expect to see RVNC reach a price target of $15, previously predicting the value of $32. The rating they have provided for RVNC stocks is “Neutral” according to the report published on March 23rd, 2020.
Goldman gave a rating of “Buy” to RVNC, setting the target price at $15 in the report published on December 2nd of the previous year.
RVNC Trading at 23.83% from the 50-Day Moving Average
After a stumble in the market that brought RVNC to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 6.57% of gains for the given period.
Volatility was left at 5.05%, however, over the last 30 days, the volatility rate increased by 4.56%, as shares surge +24.80% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +19.75% upper at present.
During the last 5 trading sessions, RVNC rose by +15.22%, which changed the moving average for the period of 200-days by +75.73% in comparison to the 20-day moving average, which settled at $27.76. In addition, Revance Therapeutics, Inc. saw 80.90% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for RVNC
Current profitability levels for the company are sitting at:
- -39820.58 for the present operating margin
The net margin for Revance Therapeutics, Inc. stands at -38602.66. The total capital return value is set at -81.54, while invested capital returns managed to touch -80.32. Equity return is now at value -89.00, with -47.20 for asset returns.
Based on Revance Therapeutics, Inc. (RVNC), the company’s capital structure generated 14.32 points at debt to equity in total, while total debt to capital is 12.53.
When we switch over and look at the enterprise to sales, we see a ratio of 1,083.65, with the company’s debt to enterprise value settled at 0.07. The receivables turnover for the company is 0.03 and the total asset turnover is 0.00. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.24.